Quantinno Capital Management LP Boosts Holdings in Haleon PLC Sponsored ADR $HLN

Quantinno Capital Management LP lifted its holdings in Haleon PLC Sponsored ADR (NYSE:HLN) by 11.8% in the first quarter, HoldingsChannel reports. The fund owned 1,221,499 shares of the company’s stock after buying an additional 128,917 shares during the period. Quantinno Capital Management LP’s holdings in Haleon were worth $12,227,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. IHT Wealth Management LLC grew its holdings in shares of Haleon by 6.9% during the 4th quarter. IHT Wealth Management LLC now owns 16,205 shares of the company’s stock valued at $164,000 after purchasing an additional 1,049 shares during the last quarter. National Bank of Canada FI lifted its stake in shares of Haleon by 6.7% in the 3rd quarter. National Bank of Canada FI now owns 17,385 shares of the company’s stock valued at $156,000 after acquiring an additional 1,099 shares during the last quarter. Oppenheimer & Co. Inc. boosted its holdings in Haleon by 4.7% during the 4th quarter. Oppenheimer & Co. Inc. now owns 24,744 shares of the company’s stock valued at $250,000 after acquiring an additional 1,100 shares during the period. Cary Street Partners Financial LLC grew its position in Haleon by 20.1% during the 2nd quarter. Cary Street Partners Financial LLC now owns 6,646 shares of the company’s stock worth $69,000 after acquiring an additional 1,113 shares during the last quarter. Finally, Advisory Services Network LLC increased its stake in Haleon by 7.1% in the 3rd quarter. Advisory Services Network LLC now owns 17,431 shares of the company’s stock worth $156,000 after purchasing an additional 1,155 shares during the period. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on HLN shares. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a research note on Thursday, April 30th. Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a research report on Tuesday, June 30th. Rothschild & Co Redburn lowered shares of Haleon from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 16th. Wall Street Zen raised shares of Haleon from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Finally, Zacks Research cut shares of Haleon from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 21st. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy”.

Haleon Price Performance

Shares of NYSE HLN opened at $9.80 on Tuesday. Haleon PLC Sponsored ADR has a 1 year low of $8.65 and a 1 year high of $11.28. The stock has a market capitalization of $43.19 billion, a P/E ratio of 25.14, a P/E/G ratio of 2.26 and a beta of 0.12. The company’s 50-day moving average is $9.45 and its 200 day moving average is $9.85. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.69 and a quick ratio of 0.52.

Haleon Cuts Dividend

The company also recently disclosed a dividend, which will be paid on Thursday, September 17th. Shareholders of record on Friday, August 14th will be given a dividend of $0.0642 per share. This represents a yield of 127.0%. The ex-dividend date of this dividend is Friday, August 14th. Haleon’s payout ratio is presently 64.10%.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.